- WHA69: Draft resolution (A69/B/CONF./7) on CEWG follow-up charts course for WHO's work on R&D
- WHO to Colombia Minister of Health: Unaffordable drug prices are a legitimate reason for issuing a compulsory license
- 28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug
- HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement
- Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug
- 15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia
- Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib
- WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies
- Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License
- 13 non-profits urge Senate HELP Committee to block floor amendments to 21st Century Cures Act counterpart
Attached is a letter from eleven of the 28 House Democrats that supported the Trade Promotion Authority (TPA) Fast Track legislation, on the topic of intellectual property rights and medicine. The letter, which is moderate and cautious in substance, but overall helpful given where negotiations stand, closes by telling Ambassador Froman that "As members who support trade done right, we strongly believe that TPP must not inhibit access to lifesaving medicines."
The World Intellectual Property Organization's (WIPO) Twenty-Second session of the Standing Committee on the Law of Patents (SCP) is taking place from 27 July 2015 to 31 July 2015 in Geneva, Switzerland. The prior session of the Committee (November 2014) ended in deadlock. Ultimately, patents and health proved to be the deciding factor.
On Wednesday, July 22, 2015, the Senate Veterans Committee held a mark-up to consider several bills. During the mark-up, Senator Sanders offered an amendment, attached below, that would create a compulsory license mechanism in the Department of Veterans Affairs, for patents on medical inventions. (See amendment text below). The motivation for the amendment was a crisis in the VA involving access to drugs for the hepatitis C virus (HCV).
On the topic of the TPP and copyright, KEI has sent a letter to Maria Pallante, the Register of Copyrights, Shira Perlmutter, Chief Policy Officer and Director for International Affairs for USPTO, and Nancy Weiss, Senior Advisor to the Chief Technology Officer, Office of Science and Technology Policy (OSTP), Executive Office of the President.
KEI asked these agencies to address certain issues in the TPP intellectual property chapter that relate to access to copyright issues, with a focus on orphan works, and uses by governments.
On Thursday, 23 July 2015, at 11AM Eastern Time (Washington, DC), KEI will host a seminar on drug pricing featuring Dr. Ruth Lopert, the Deputy Director of Pharmaceutical Policy and Strategy at the Center for Pharmaceutical Management, at Management Sciences for Health (MSH).
EU Trade Commissioner Backs LDC Request for TRIPS Exemption for Pharmaceuticals Until Graduation from LDC StatusSubmitted by thiru on 16. July 2015 - 9:35
In a comprehensive, 2000 word speech to the European Parliament's International Trade Committee (INTA) on Modernising Trade Policy - Effectiveness and Responsibility, European Trade Commissioner, Cecilia Malmström, cast a wide net in her speech covering in her words, 1) the "benefits of trade for all: our economy in general, consumers, entrepreneurs, SMEs and the poorest countries", 2) "trade policy's commitment to our values in the world, supporting our foreign policy, promoting the respect of human rights, soci
On 20 March 2015, the European Union published a position paper on intellectual property outlining its priorities for the Transatlantic Trade and Investment Partnership (TTIP). At the time of publication of this position paper, the EU noted that "the U.S. has not yet formally identified the areas of interest that it could consider as priorities."
10th TTIP Stakeholder Event, Round 10
SESSION 2 Issues related to intellectual property including Geographical Indications and public health
15 July 2015
Knowledge Ecology International
A Positive Agenda for TTIP
My presentation today will address creating a positive agenda for TTIP focusing on the following six themes
1. Cooperation in funding R&D as a public good
2. Promoting the transparency of drug development costs, revenues, and prices
3. Standards for putting government funded research data and articles into free public archives
Attached below is a letter KEI sent to Emily Bleimund, Senior Policy Advisor for International Trade for the Department of Health and Human Services (HHS), and several other U.S. trade officials. The letter addresses three issues in the TPP text:
- There is a need for exceptions to exclusive rights in pharmaceutical and biologic drug test data.
- WTO standards for compulsory licenses should not be modified as part of a secret negotiation, or constrained by a 3-step test.
Standing Committee on the Law of Patents (SCP) - GRULAC proposal - Revision of 1979 WIPO Model Law for Developing CountriesSubmitted by thiru on 10. July 2015 - 2:47
The World Intellectual Property Organization's (WIPO) Twenty-Second session of the Standing Committee on the Law of Patents (SCP) will be convened from 27 July 2015 to 31 July 2015 in Geneva, Switzerland. For consideration of the Committee, the Group of Latin American and Caribbean Countries (GRULAC) have submitted a proposal entitled, Revision of 1979 WIPO Model Law for Developing Countries on Inventions (SCP/22/5).
July 2015: WTO reports on EU competition policy and copyright law - WTO Trade Policy Review - European UnionSubmitted by thiru on 9. July 2015 - 9:35
On 6 July 2015 and 8 July 2015, the World Trade Organization (WTO) conducted a trade policy review of the European Union. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). As noted by the WTO secretariat, the "basis for the review is a report by the WTO Secretariat and a report by the Government of the European Union" (Source: Trade Policy Review - European Union, July 2015).
The SCCR failed to adopt these recommendations. The dipcom in 2017 recommendations in Item 6 was too strong, and the exceptions recommendations for items 7 and 8 were too weak.
Also Attached as pdf
Proposed Recommendations SCCR/30
Proposed Recommendation Agenda Item 6:
Attached is the document the chair distributed as the summary of the week long SCCR 30 meeting.